VolitionRX Ltd.

As of November 14, 2024, VolitionRX Ltd. is rated as risky due to significant overvaluation indicated by negative valuation ratios and a poor 3-year return of -62.40%, underperforming the S&P 500's 70.41%.

As of November 14, 2024, VolitionRX Ltd. is considered "risky" and overvalued due to negative financial ratios, including a Price to Book Value of -2.06 and an EV to EBITDA of -2.67, despite a recent stock performance that outpaced the S&P 500.

As of June 20, 2025, the technical trend is mildly bullish, supported by positive weekly and monthly MACD and Bollinger Bands, despite some short-term weakness indicated by the weekly RSI and daily moving averages.

As of March 2022, the management team of VolitionRX Ltd. includes Dr. Martin Faulkes (Executive Chairman), Mr. Cameron Reynolds (President and CEO), and several independent directors: Dr. Phillip Barnes, Dr. Salvatore Butera, Dr. Alan Colman, Dr. Edward Futcher, and Mr. Guy Innes. This team provides governance and strategic direction for the company.

VolitionRX Ltd. is a clinical-stage life sciences company developing blood-based diagnostic tests for cancer and other diseases, with a market cap of $67.17 million and recent net sales of $0 million. As of March 2025, it reported a net loss of $5 million.

As of Jun 18, VolitionRX Ltd. has a market capitalization of 67.17 million and reported net sales of 1.31 million, with a net loss of 24.27 million over the last four quarters. The company's balance sheet shows shareholder's funds of -24.91 million and total assets of 9.40 million.